APOE2 gene findings open new path for Alzheimer's drugs
Scientists have discovered how the longevity-linked APOE2 gene protects brain cells from Alzheimer's, opening a new avenue for drug developers to target DNA repair rather than amyloid plaques.
Researchers at the Buck Institute for Research on Aging have identified the biological mechanism that allows the APOE2 gene variant to protect against Alzheimer's disease and extend lifespan. Published in Aging Cell, the study shows that APOE2 helps neurons prevent and repair DNA damage while resisting cellular senescence, a deteriorated state linked to neurodegeneration.
The finding represents a potential pivot point for the pharmaceutical sector. For years, Alzheimer's drug development has focused heavily on amyloid-beta biology and lipid transport. This research suggests that therapies mimicking APOE2's ability to defend the neuronal genome could be a viable alternative, particularly for patients carrying the high-risk APOE4 variant.
Scientists engineered human stem cells to carry the APOE2, APOE3, or APOE4 variants. Though the variants differ by only two amino acids, APOE2 neurons showed significantly less DNA damage and strongly activated genetic repair pathways. Under severe stress from radiation or chemotherapy drugs, APOE2 cells also maintained healthier internal structures and avoided the cellular aging program seen in other variants.
Crucially for commercial drug development, this protection appears to be transferable. When researchers added recombinant APOE2 protein to APOE4 neurons, the higher-risk cells showed reduced DNA damage after radiation exposure. Similar protective signs of healthier cellular aging were also found in the brain tissue of older mice engineered with the human APOE2 gene.
"Until now, the APOE field has focused largely on lipid handling and amyloid-beta biology," said Lisa M. Ellerby, the senior author and a professor at the Buck Institute. "By showing that APOE alleles also tune how neurons defend their genome, this study connects a major longevity gene to two of the most actively studied hallmarks of aging."
As Europe's population ages, the economic burden of dementia continues to climb. The prospect of APOE2-mimetic compounds or targeted DNA repair treatments offers a tangible new target for biotech firms, shifting investment focus toward senescence and genome stability in the search for effective therapies.
